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Background and Aims: We compared the immediate and one-year results as well as total hospital costs 28 
between catheter-directed thrombolysis (CDT) and pharmacomechanical thrombolysis (PMT) in the 29 
treatment of symptomatic upper extremity deep venous thrombosis (UEDVT). 30 
Material and Methods: From 2006 to 2013, 55 patients with UEDVT were treated with either CDT or 31 
PMT at Helsinki University Hospital. Of them, 43 underwent thoracoscopic rib resection later in order to 32 
relieve phlebography-confirmed vein compression. This patient cohort was prospectively followed up 33 
with repeated phlebographies. CDT was performed to 24 patients and 19 had PMT with a Trellis™ 34 
device. Clinical evaluation and vein patency assessment were performed with either phlebography or 35 
ultrasound one year after the thrombolysis. Primary outcomes were immediate technical success, one-36 
year vein patency, and costs of the initial treatment. 37 
Results: The immediate overall technical success rate, defined as recanalization of the occluded vein and 38 
removal of the fresh thrombus, was 91.7% in the CDT group, and 100% in the PMT group (n.s.). The 39 
median thrombolytic time was significantly longer in CDT patients than PMT patients (21.1 hours vs. 40 
0.33 hours, P<0.00001). There were no procedure-related complications. The one-year primary assisted 41 
patency rate was similar in both groups (91.7% and 94.7%, respectively). There were no recurrences of 42 
clinical DVT. The hospital costs for the acute period were significantly lower in the PMT group than the 43 
CDT group (medians 11,476 € and 5,975 € in the in the CDT and PMT group, respectively (P<0.00001)). 44 
Conclusions: The clinical results of the treatment of UEDVT with CDT or PMT were similar. However, 45 
PMT required shorter hospital stay and less intensive surveillance, leading to lower total costs. 46 
 47 
Key words: Upper extremity deep venous thrombosis, thrombolysis, thrombectomy, catheter-directed 48 




















Upper extremity deep vein thrombosis (UEDVT) represents approximately 2–3% of all deep vein 53 
thromboses (1). Primary UEDVT includes idiopathic and effort-related thrombosis (Paget–Schroetter 54 
syndrome). Effort-related UEDVT may be related to abnormal anatomy, or it may be a consequence of 55 
strenuous activity (2). Secondary UEDVT is mostly related to central venous catheters, pacemaker 56 
devices, or malignancy (3). 57 
 58 
The clinical manifestations of UEDVT include edema of the affected extremity in 80%, extremity pain in 59 
30%–50%, and erythema in approximately 15% of the patients (4). Approximately 5% of patients have 60 
no symptoms (5,6). The incidence of post-thrombotic syndrome (PTS) in the upper limb ranges from 7% 61 
to 46%, and PTS may result in significant morbidity, especially if it occurs in the dominant arm (7). 62 
Treatment with anticoagulant therapy alone is associated with delayed resolution of acute symptoms, 63 
reduced venous outflow, and increased incidence of residive thrombus, chronic venous obstruction, 64 
venous valvular incompetence, and subsequent venous hypertension (8). Systemic thrombolysis has 65 
been associated with major hemorrhagic problems. In order to reduce the thrombolytic therapy dose 66 
and the bleeding risk, American College of Chest Physicians (ACCP) guidelines encourage catheter-based 67 
thrombolysis over systemic infusion in treatment of UEDVT with severe symptoms; with thrombus 68 
extending most of the subclavian and the axillary vein, symptoms for <14 days, good functional status, 69 
life expectancy of > 1 year, and a low risk for bleeding (9). 70 
 71 
CDT has also been associated with major systemic hemorrhage, and long infusion times (8). PMT with 72 
the Trellis™ device (Trellis™ Peripheral Infusion System, Covidien, Mansfield, MA, USA) intended to 73 

















thrombolysis within an isolated zone. However, due to problems with the sterilization process and 75 
errors in marking of the balloons, Trellis was withdrawn from the market in xxxx. The current study was 76 
conducted prior to the withdrawal. To our knowledge, this is the only study comparing PMT and CDT for 77 
UEDVT. 78 
 79 
We report the immediate and mid-term results as well as the total hospital costs between conventional 80 
CDT and PMT with the Trellis™ device in the treatment of symptomatic UEDVT. 81 

















 MATERIAL AND METHODS 83 
 84 
From 2006 to 2013, 72 patients with UEDVT were seen at the Helsinki University Hospital. All patients 85 
were clinically assessed and  duplex ultrasonography (DUS) was used as the primary diagnostic method. 86 
The coagulation profile was assessed at the time of the first visit. Computed tomography (CT) and 87 
magnetic resonance imaging (MRI) were used in patients with inconclusive duplex data or if a pulmonary 88 
embolism was suspected. Of the 72 patients, 17 with minimal symptoms were treated conservatively 89 
using low-molecular-weight heparin (LMWH), and 55 patients with more severe symptoms were treated 90 
invasively, with either CDT or PMT using the Trellis™ device. After CDT/PMT, all patients underwent 91 
completion phlebography with provocation tests in order to assess the technical success and 92 
completeness of the thrombolysis/thrombectomy, as well as a possible vein compression. Technical 93 
success was defined as successful recanalization of the occluded vein and removal of the fresh 94 
thrombus. Completeness of the thrombolysis/thrombectomy was graded to three classes: “complete” if 95 
phlebography showed no further clot, “partial” if thrombolysis was incomplete, but less than 50% of the 96 
thrombus remained, and “failed” when more than 50% of the thrombus was present after the 97 
intervention (11,12). To detect compression, phlebography was performed both at rest (full adduction) 98 
and at provocation (arm 90 degrees abducted with external rotation “hand-on-head position”). 99 
 100 
As a second stage procedure, forty three (78.2%) of 55 patients who underwent early clot removal 101 
underwent a thoracoscopic first rib resection due to an external compression of the vein detected in 102 
post-thrombolysis phlebography (13). They were included in a prospective rib resection surveillance 103 
program, which was analysed retrospectively from hospital records. The surveillance protocol included 104 
both clinical control and patency examinations with DUS and phlebography, as well as an assessment for 105 


















Twelve (12%) of the 55 patients underwent local thrombolysis only with no rib resection and were 108 
excluded, because there was no systematic follow-up imaging available for these patients. The reasons 109 
being malignancy in 2 patients, lack of extrinsic compression in control phlebography in 5 patients, local 110 
foreign material (pacemaker) in 2 patients, and chronic occlusion of the subclavian vein in 3 patients (all 111 
three had thrombophilia and minimal or no symptoms after CDT) (Figure 1).  112 
Twenty-four of the study patients underwent CDT and 19 had PMT. In the beginning of the study period, 113 
in 2006 until 2012, CDT was used routinely. Since 2012, the Trellis™ device was introduced in our 114 
institution and became more popular. Patient selection was thus partly time-dependent; and, towards 115 
the end of the study period, depended upon whether the radiologist performing the procedure was 116 
familiar with the PMT procedure or not. Phlebographic images obtained at the time of treatment and 117 
during the follow-up were carefully reviewed.    118 
To assess mid-term results, one-year duplex scan reports as well as phlebography images and reports 119 
were evaluated. Duplex scan only was performed to 25 patients, phlebography only to 12 patients and 120 
both duplex and phlebography to 6 patients mostly due to inconclusive result of duplex. In the end the 121 
mid term patency assessment was based on duplex scan in 25 cases and phlebography in 18 patients. 122 
 123 
The end points were immediate technical success and one-year vein patency. Successful PTA was 124 
defined as residual stenosis of 0-20%. 125 
 126 
The detailed hospital costs for all patients during lysis admission time were collected from the hospital 127 




















Treatment options 132 
A Catheter-directed thrombolysis 133 
Percutaneous access was achieved with ultrasound guidance primarily through the basilic vein and 134 
secondarily through the cephalic, brachial, or cubital veins, using a 4-French sheath. A 0.035’’ 135 
hydrophilic wire (Radiofocus guide wire M, Terumo Co., Japan) was passed through in the CDT group, 136 
and a diagnostic phlebography was performed to assess the lesion, its extension, and the presence of 137 
collaterals. 138 
 139 
A single dose of alteplase (10 mg) was administered through a multi-hole catheter (tähän katetrin 140 
tiedot) into the occlusion, and infusion at a rate of 1 mg/hour was started. The patient was observed at 141 
the intermediate care unit. After approximately 24 hours of thrombolysis, a second phlebography was 142 
performed to assess the lytic success and the need to continue thrombolysis for an additional 24 hours. 143 
In the final phlebography, the need for balloon angioplasty was assessed and in case of a significant 144 
stenosis a 8-12mm balloon was used (Figure 2).  145 
 146 
B Pharmacomechanical thrombectomy 147 
The access technique and assessment of the lesion were similar to the CDT procedure. The Trellis™ 148 
catheter was positioned over a 0.035” guide wire through an 8-Fr sheath, leaving the area of treatment 149 
between the two inflated balloons. Thereafter, 6–10 mg of alteplase was injected through the side holes 150 
of the device catheter and a rotational technique started to disrupt the thrombus. For the next 10–20 151 
minutes, alteplase was injected slowly to promote thrombolysis. Finally, the melted thrombosis was 152 
aspirated with a 50-ml syringe through the side hole and the vein was evaluated with a manual injection 153 

















lysis was continued using 6–10 mg of alteplase for another 10–20 minutes. The maximum amount of 155 
alteplase was 20 mg. Seventeen (89%) patients had a single-session lysis. In 16 patients, the lysis lasted 156 
for 20 minutes and for 3 patients, 10 minutes due to a short occlusion with a small thrombus. Two (11%) 157 
patients required 2 sessions lasting a total of 30–35 minutes. Completion phlebography, possible PTA 158 
and anticoagulation were similar to the CDT group. Patients treated with PMT had no need for a stay in 159 
an intermediate care unit. 160 
 161 
Low molecular weight heparin was started with a dose 1mg/kg twice a day immediately when the 162 
diagnosis was made and continued during the CDT and PMT. After thrombolysis, the patients were kept 163 
on LMWH and warfarin until the INR reached 2–2.5, after which warfarin treatment was continued for 164 
3–6 months. 165 
 166 
The surgical decompressions were later performed with a video-assisted thoracoscopic first rib resection 167 
(VTRR) technique. The procedure is described in detail elsewhere (13).  168 
 169 
Statistical analysis 170 
SPSS 22.00 was used in the statistical analysis. Continuous variables are expressed as median values 171 
(range). The prevalence of risk factors is expressed as percentages. Comparisons between the groups 172 
were made using the Mann–Whitney U test (continuous variables) and chi-square test (dichotomic 173 
variables).     174 
The study protocol has been accepted by the Institutional Review Board (HUS/214/2016). Because of 175 
the retrospective nature of this study, no informed consent was obtained from the study subjects. 176 
 177 


















The CDT group included 24 patients with a median age of 31 years, and the PMT group included 19 180 
patients with median age of 26. There were no significant differences in patient demographics between 181 
the groups. The most common symptoms were swelling, pain, and numbness of the affected extremity, 182 
with an equal prevalence in the groups (Table I). Duplex US was used as the first diagnostic examination 183 
in 41 patients (95%), while additional imaging was employed in 5 (12%): MRI in 2, and CT in 3 patients. 184 
The median time between symptom onset and intervention was 4.5 days (range 1–12 days) and 4 days 185 
(range 1–7 days) in CDT and PMT groups, respectively (n.s.). The median thrombosis length in treated 186 
patients with Trellis™ was 116 mm (range 30-225 mm), and in the CDT group the median lesion length 187 
was 160.5 mm (range 45-254 mm). The median time from the early clot removal to the rib resection was 188 
92 days (range, 10-458 days), 68.5 days (range, 15-458 days) in the CDT group and 120 days (range, 10-189 
265 days) in the PMT group. 190 
 191 
 192 
Immediate technical success 193 
Immediate overall technical success was 92% and 100% in the CDT and PMT groups, respectively. In the 194 
PMT group, complete lysis was achieved in 17 (90%) and partial lysis in 2 (11%) patients. In the CDT 195 
group, the therapeutic response was complete in 19 (79%) and partial in 3 (13%) cases, while the 196 
treatment failed in 2 (8%). The residual lesion after thrombolysis and the change in the lesion’s 197 
topography before rib resection are shown in Table II. 198 
 199 
In 2 patients (8%), the treatment was started with CDT, but due to persistent thrombosis after two days 200 
of thrombolysis, PMT was successfully initiated to remove the residual thrombosis. Ten (42%) patients in 201 

















significant stenosis in the completion phlebography. The immediate phlebographic results are presented 203 
in Table II. There was no pulmonary embolism found in the CT scan in patients with a clinical suspicion of 204 
PE, or other major complications during the hospital stay after either of the procedures. The treatment 205 
parameters of the PMT and CDT patients are shown in Table III. 206 
 207 
One-year follow-up for vein patency 208 
After a median follow-up of 13 months (range 10–36), the vein patency was assessed either by 209 
phlebography (n=18) or duplex US (n=25). A good flow with no significant stenosis (<20%) was observed 210 
in 18 (75%) patients in the CDT group, and in 17 (90%) patients in the PMT group (n.s.). No significant 211 
difference in symptoms or technical success were seen at one year (Table IV). During the follow-up 212 
period, 11 (46%) patients in the CDT group and 10 (53%) patients in the PMT group (ns) underwent 213 
balloon angioplasty due to stenosis >20% or occlusion associated persistent symptoms (Table IV). No 214 
stents were used. The overall assisted primary patency at one year was 92% (n=22) in the CDT group and 215 
95% (n=18) in the PMT group (ns). No patients suffered a recurrence of clinical DVT during the follow-216 
up. 217 
 218 
Total hospital costs 219 
The median total procedural cost of the hospital stay per patient was 6,986 (range 6,100–8,564) € in the 220 
CDT group and 4,499 (range 3,782–5,120) € in the PMT group, P< 0.001. The median total hospital cost 221 
was 11,476 (range 8,468–17,467) €/patient in the CDT group and 5,975 (range 4,763–7,395) €/patient in 222 




















In acute UEDVT, both CDT and PMT are effective treatment methods and work more quickly than 227 
anticoagulation in the recanalization of the occluded vein (8,10). Studies on the results of PMT are 228 
scarce. We report a consecutive case series of 43 patients with symptomatic UEDVT who underwent 229 
invasive treatment with either CDT or PMT using a Trellis™ device and a thoracoscopic rib resection 230 
thereafter. We compared the safety, efficacy, one-year results, and total hospital costs of the two 231 
treatment methods. We found that PMT was associated with a significantly shorter treatment time, as 232 
well as lower total hospital costs than CDT, with similar safety, efficacy, and one-year results. 233 
Furthermore, the immediate phlebographic success was more often successful after PMT. 234 
 235 
Our results are comparable with those reported in previous publications comparing CDT and PMT, 236 
although the majority of the patients in these studies have had lower-extremity DVT (LEDVT) (10,14). 237 
Kim et al. compared CDT and PMT in the treatment of 23 UEDVT and 44 LEDVTs in 36 patients (14). 238 
Catheter-directed thrombolysis was performed in 40 cases and pharmacomechanical thrombectomy 239 
with an Angiojet rheolytic thrombectomy catheter in 27 cases. The mean duration of the treatment was 240 
significantly longer in CDT when compared to PMT—48 and 26 hours, respectively. In addition, the 241 
consumption of urokinase was significantly lower in PMT. The authors achieved complete clot lysis in 242 
73% using CDT and 82% with PMT. Lin et al., in turn, compared CDT and PMT with an Angiojet rheolytic 243 
thrombectomy system in 98 patients (10). They reported complete lysis of the thrombus in 75% of the 244 
patients after PMT versus 70% after CDT (n.s.) and partial lysis in 25% and 30% of the patients, 245 
respectively. 246 
 247 
The largest benefit of PMT in comparison to CDT is the need for minimal or no intermediate care unit 248 
treatment and a shorter hospital stay. None of our PMT patients needed to be admitted to an 249 

















average of 2 days of treatment in the intermediate care unit, which was the duration of thrombolysis; 251 





The delay between the onset of symptoms and treatment has an impact on the success of thrombus 255 
removal. If thrombolysis is performed within a few days, the primary success rate is close to 100%. After 256 
two weeks, the success rate decreases to 85%; and after 6 weeks, down to 50% (15,16).
 
 The ACCP 257 
guidelines recommend that local thrombolysis should be performed in patients with severe symptoms 258 
of recent onset (<14 days) if appropriate expertise and resources are available (9). In our study, the 259 
median time between symptom onset and intervention was approximately 4 days in both groups. 260 
Probably due to the relatively short delay, we had a high immediate technical success rate with an 261 
overall thrombus removal of 100% in the PMT group and 92% in the CDT group (n.s.). 262 
 263 
In many studies, the major drawback of CDT therapy has been hemorrhagic complications, which have 264 
been related to prolonged treatment duration (17-23). Our CDT patients received a median of 21 hours’ 265 
infusion of the thrombolytic agent, as opposed to 20 minutes in PMT patients. We did not observe any 266 
bleeding complications, probably due to the small sample size. 267 
 268 
The aim of CDT and PMT is to open the occluded vein and achieve immediate relief of the symptoms. 269 
However, long-term patency of the treated vein is also important. If a significant stenosis persists in 270 
provocation phlebography, a risk of rethrombosis exists and our treatment of choice is to perform a 271 
thoracoscopic first rib resection, and a postoperative balloon angioplasty of the vein when appropriate 272 
(13,23). The focus of this paper was to compare two different treatment options in the acute phase. 273 

















these patients because even if data are sparse in the literature, stent fractures have been found to be 275 
common in this position (24).
 
 276 
We used the Trellis™ device to achieve PMT with no major difficulties or complications. Unfortunately, 277 
the device was later withdrawn from the market. However, other devices for pharmacomechanical 278 
thrombectomy are still available. The results with the Angiojet rheolytic (Possis Medical, Minneapolis, 279 
MN) thrombectomy device are comparable to ours (10,11). We have had good experiences with PMT, 280 
the main benefit being the savings in intermediate care, and are now looking for a suitable device for 281 
routine use. 282 
 283 
The main limitation of our study is the small number of patients. Furthermore, the length of follow-up 284 
was limited. The treatments were performed during different time periods: CDT was used in the 285 
beginning of the study period and the method then changed to PMT, which was mostly used in the 286 
latter period. CDT has been performed in our institution for years in both upper and lower extremities 287 
and the procedure was familiar to all interventional radiologists. Alltogether 7 interventionalists was 288 
performing CDT in this material. However, as PMT was initiated during the study period, there might be 289 
some learning curve effect. However, when started, all PMTs were performed by 2 interventional 290 
radiologists made all except three Trellis PMTs in this study. However, Otherwise nothing else in the 291 
treatment protocol changed; patients underwent similar rib resection after the initial treatment, and the 292 
medication after thrombolysis/thrombectomy was the same. In the beginning of this study, a 293 
phlebographic protocol before and after rib resection was designed, and we chose to include only 294 
patients with a complete phlebographic work-up. 295 



















The immediate and one-year clinical results of the treatment of subclavian vein thrombosis with CDT 299 
and PMT are equal. However, the need for admission to an intermediate care unit, hospital stay, as well 300 
as multiple phlebographic sessions and prolonged thrombolysis, were significantly more infrequent in 301 
patients treated with PMT than with CDT, leading to significantly lower total costs. 302 
 303 
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FIGURE LEGENDS 363 
Figure 1. Patient flow. 364 
Figure 2. A Phlebography showing thrombosis of the axillo-subclavien segment. B Post-thrombolysis 365 
control phlebography with patent veins and a partial success (less than 50% thrombus remaining). C 366 
Angioplasty after local  thrombolysis using PMT. D Mid-term phlebography with open veins. 367 














Table I. Demographic data and initial symptoms before thrombolysis. There were no significant 
differences between the groups. 
  PMT CDT 
Number of patients 19 24 
Age (median, IQR) 26 (17-54) 31 (23-49) 
Male: Female 9:10 12:12 
Effort history* n (%) 13 (68%) 21 (88%) 
Thrombophilia n (%) 3 (16%) 4 (17%) 
Family history n (%) 4 (21%) 5 (21%) 
RT UL n (%)  12 (63%) 17 (71%) 
LT UL n (%)  7 (37%) 7 (29%) 
Arm pain 17 (90%) 22 (92%) 
Arm swelling 19 (100%) 24 (100%) 
Arm numbness 11 (58%) 14 (58%) 
Arm weakness 2 (11%) 2 (8%) 
Neck swelling 1 (5%) 2 (8%) 
Dilated neck veins 1 (5%) 7 (29%) 
Positive provocation test 15 (79%) 20 (83%) 
Pulmonary embolism  0 (0%) 1 (4%) 
Paresthesia  4 (21%) 7 (29%) 
PMT, pharmacomechanical thrombolysis; CDT, catheter-directed thrombolysis;  
RT UL, right upper limb; LT UL, left upper limb. 
*Heavy upper limb exercise as a probable etiology. 














Table II. Phlebographic results. 
 Degree of success of lysis (11,12) PMT CDT p-value 
Complete  lysis >99% 17 (90%) 19 (79%) NS 
Partial lysis (50%-99%) 2 (11%) 3 (13%) NS 
Unsatisfactory  lysis <50% / change line of 
treatment   
0 (0%) 2* (8%) NS 
 
Degree of residual stenosis after thrombolysis 
 
   
No lesion/stenosis <20% 13 (68%) 7 (29%) 0.010 
Moderate stenosis 20%-49% 4 (21%) 5 (21%) NS 
Significant stenosis 50%/>50% 2 (11%) 10 (42%) 0.024 
Occlusion  0 (0%) 2 (8%) NS 
 
Pre-rib resection phlebographic findings ** 
     
No lesion/stenosis <20% 14 (74%) 8 (33%) 0.009 
Moderate stenosis 20%-49% 2 (11%) 3 (13%) NS 
Significant stenosis 50%/>50% 3 (16%) 10 (42%) NS 
Occlusion  0 (0%) 3 (13%) NS 
 
Re-thrombosis (pre rib resection)  
0 (0%) 0 (0%) NS 
NS, not significant; CDT, catheter directed thrombolysis; PMT, pharmacomechanical thrombectomy. 
*Changed to Trellis 
**This phlebography was done prior to thoracoscopic first rib resection (median time from thrombolysis to rib 
resection was 90.5 days, range 10–450 days). 
 #P-value=0.011, tested with chi-square for the combined numbers of significant and occlusions. 
















Table III. Treatment parameters, use of recources and costs in patients treated with PMT and/or CDT. 
 
Treatment group PMT  CDT P value 
 Infusion time 0.33 h (0.17–0.58 h) 21.12 h (16.11–47.25 h) < 0.00001 
Total alteplase dose 6 mg (6–15 mg) 32 mg (20–55.3 mg) < 0.00001 
Intermediate care unit (h) 0 48 h (48–72) < 0.00001 
Number of phlebographies 1 2 (2–3) < 0.00001 
Angiography and/or 
Interventional suite costs   
4499.00 € (3782€-5120€) 6985.50 € (8564€-6100€) < 0.00001 
Length of hospital admission  3 days (1–8 days) 6 days (3–15 days) 0.0061 
Total hospital costs  5975.00 € (4763€–7395€) 11476.00 € (8468€–17467€) < 0.00001 
CDT, catheter-directed thrombolysis; PMT, pharmacomechanical thrombectomy. 













Table IV. One-year vein patency and symptom status. No significant differences were seen. 
 
PMT 
N = 19 
CDT 
N = 24 
p-value 
Treatment method    
Good flow no lesion/stenosis <20% 17 (90%) 18 (75%) NS 
Moderate stenosis (20%-49%) 1 (5%) 2 (8%) NS 
Significant stenosis (50%/ > 50%) 0 (0%) 1 (4%) NS 
Occlusion  1 (5%) 3 (13%) NS 
Any PTA during the FU 10 (53%) 11 (46%) NS 
Good results of PTA  8/10 (80%) 10/11 (91%) NS 
Recoil/Failed PTA  2/10 (20%) 1/11 (9%) NS 
Patency in the final phlebography  18 (95%) 22 (92%) NS 




 No symptoms 15 (79%) 16 (67%) NS 
 Pain during rest 0 (0%) 0 (0%) NS 
 Pain during exercise 1 mild (5%) 3 mild (13%) NS 
 Swelling 1 mild (5%) 2 mild (8%) NS 
 Numbness 2 mild (11%) 3 mild (13%) NS 
 Paresthesia 0 (0%) 0 (0%) NS 
 Weakness 0 (0%) 0 (0%) NS 
 Complete improvement 15 (79 %) 16 (67%) NS 













 Overall improvement 19 (100%) 24 (100%) NS 
 
NS, not significant; CDT, catheter directed thrombolysis; PMT, pharmacomechanical thrombectomy. 





















CDT / PMT 
N=55 








UEDVT = upper extremity deep venous thrombosis; CDT = catheter-directed thrombolysis; LMWH = low 
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